Wound care company Odinwell will primarily use the proceeds from the fully subscribed directed issue for the commercialization of the veterinary product novaQS, CEO Marcus Andersson tells Finwire. The company previously announced that the issue to the board and management would provide SEK 670,000 before issue costs.According to Andersson, the focus is now shifting from development to market introduction and sales. The capital will be used for scaling up production, quality assurance, as well as marketing and sales activities.Together with the larger directed issue carried out earlier, the capital is considered to give the company good conditions to launch novaQS and reach the next planned milestones.